Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Blood blood.2024025945.

https://doi.org/10.1182/blood.2024025945

Published: 2024

Includes: Supplemental data

Journal Articles

A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Blood (2023) 142 (Supplement 1): 1004.

https://doi.org/10.1182/blood-2023-174506

Published: 2023

Journal Articles

Paired Analysis from Patients with Myeloma Elucidates Favorable CAR-T Manufacture and Phenotype, Starting from Mobilized Pre-Transplant Apheresis Vs. Non-Mobilized Apheresis after Four Prior Lines

Ciara Louise L. Freeman, Julieta Abraham Miranda, Meghan Menges, Jerald Noble, Hien Liu, Salvatore Corallo, Albert J Ribickas, Constanza Savid-Frontera, Gabriel De Avila, Omar Castaneda, Jose L. Ochoa-Bayona, Rachid Baz, Doris K. Hansen, Melissa Alsina, Kenneth H. Shain, Taiga Nishihori, Reginald Atkins, Frederick L. Locke

Blood (2023) 142 (Supplement 1): 1931.

https://doi.org/10.1182/blood-2023-187539

Published: 2023

Journal Articles

Teclistamab Induces Favorable Responses in Patients with Relapsed and Refractory Multiple Myeloma after Prior BCMA-Directed Therapy

Ariel F. Grajales-Cruz, Omar Castaneda, Doris K. Hansen, Mariola A Vazquez-Martinez, Brandon Blue, Sushmita Khadka, Hien Liu, Jose L. Ochoa-Bayona, Ciara Louise L. Freeman, Frederick L. Locke, Taiga Nishihori, Kenneth Shain, Rachid Baz, Melissa Alsina

Blood (2023) 142 (Supplement 1): 3351.

https://doi.org/10.1182/blood-2023-184928

Published: 2023

Journal Articles

Selinexor Disrupts Epigenetic Programing and Modulates Immunogenicity in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3301.

https://doi.org/10.1182/blood-2023-190658

Published: 2023

Journal Articles

A Novel Composite Endpoint of Toxicity- and Progression-Free Survival after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3336.

https://doi.org/10.1182/blood-2023-184406

Published: 2023

Journal Articles

Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium

Blood (2023) 142 (Supplement 1): 4880.

https://doi.org/10.1182/blood-2023-187440

Published: 2023

Journal Articles

Unveiling the Digital Landscape of CAR-T Therapies in Multiple Myeloma Using Social Media Insights

Doris K. Hansen, Yi-Hsuan Liu, Xiaoxiao Lu, Stephen Huo

Blood (2023) 142 (Supplement 1): 7368.

https://doi.org/10.1182/blood-2023-189092

Published: 2023

Journal Articles

Clinician and Administrator Perspectives on Chimeric Antigen Receptor (CAR) T-Cell Therapy Outpatient Administration in Relapsed or Refractory Multiple Myeloma (RRMM) in the United States (US): A Qualitative Study

Doris K. Hansen, Binod Dhakal, Mehdi Hamadani, David Dingli, Tania Jain, Yi-Hsuan Liu, Kevin C De Braganca, Nicole Lodowski, Jennifer Sander Kirschenbaum, Peter Okorozo, Lindsay McFarland, Matthew Perciavalle, Stephen Huo, Krina K. Patel

Blood (2023) 142 (Supplement 1): 7274.

https://doi.org/10.1182/blood-2023-178668

Published: 2023

Journal Articles

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

Kai Rejeski, Doris K. Hansen, Yucai Wang, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, Fabian Mueller, Wolfgang Andreas Bethge, Javier L. Munoz, Razan Mohty, Veit L. Buecklein, Pere Barba, Frederick L. Locke, Yi Lin, Michael D. Jain, Marion Subklewe

Blood (2023) 142 (Supplement 1): 359.

https://doi.org/10.1182/blood-2023-180607

Published: 2023

Journal Articles

Single Cell RNA Sequencing of Sequential Samples before and after BCMA-Directed CAR-T Reveal Features Associated with Non-Durable Response, Exhausted T-Cells and Decreased Expression of Genes Encoding Key Surface Targets in Particular in Patients with Extramedullary Disease

Ciara Louise L. Freeman, Xiaohong Zhao, Mark B Meads, Jerald Noble, Raghunandan Reddy Alugubelli, Rafael Renatino-Canevarolo, Oliver Hampton, Praneeth Reddy Sudalagunta, Ariosto Siqueira Silva, Rachid Baz, Melissa Alsina, Doris K. Hansen, Xiaofei Song, Kenneth H. Shain

Blood (2023) 142 (Supplement 1): 3304.

https://doi.org/10.1182/blood-2023-191013

Published: 2023

Journal Articles

Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1027.

https://doi.org/10.1182/blood-2023-181762

Published: 2023

Journal Articles

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3499.

https://doi.org/10.1182/blood-2023-187565

Published: 2023

Journal Articles

Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma

Doris K. Hansen, Santosh Gautam, Marie-Hélène Lafeuille, Carmine Rossi, Bronwyn Moore, Anabelle Tardif-Samson, Philippe Thompson-Leduc, Alex Z. Fu, Annelore Cortoos, Shuchita Kaila, Rafael Fonseca

Blood (2023) 142 (Supplement 1): 543.

https://doi.org/10.1182/blood-2023-187233

Published: 2023

Journal Articles

Expression of Cell Surface Immunotherapy Targets across the Multiple Myeloma Disease Spectrum: Implications for Sequencing and Multi-Target Strategies

Blood (2023) 142 (Supplement 1): 4678.

https://doi.org/10.1182/blood-2023-185930

Published: 2023

Journal Articles

A Novel Composite Endpoint of Toxicity-Free, Progression-Free Survival (TPFS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1776.

https://doi.org/10.1182/blood-2023-185117

Published: 2023

Journal Articles

Cost per Responder Analysis of Patients with Lenalidomide-Refractory Multiple Myeloma Who Received Cilta-Cel from the Cartitude-4 Trial

Doris K. Hansen, Xiaoxiao Lu, Omar Castaneda, Sonja Sorensen, Saad Z Usmani, Eileen Zhang, Stephen Huo, Sundar Jagannath

Blood (2023) 142 (Supplement 1): 5083.

https://doi.org/10.1182/blood-2023-181179

Published: 2023

Journal Articles

Facility-Related Healthcare Resource Utilization (HCRU) for Patients Treated with Idecabtagene Vicleucel (Ide-Cel, bb2121) in a Real-World (RW) Setting: A Single-Center Experience

Blood (2023) 142 (Supplement 1): 5081.

https://doi.org/10.1182/blood-2023-173812

Published: 2023

Journal Articles

Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

Taiga Nishihori, Doris K. Hansen, Hien D. Liu, Omar Alexis Castaneda Puglianini, Ciara L. Freeman, Brandon J. Blue, Jason Brayer, Jongphil Kim, Ariel F Grajales-Cruz, Jose Ochoa, Rachid C. Baz, Kenneth H. Shain, Frederick L. Locke, Melissa Alsina

Blood (2022) 140 (Supplement 1): 5174–5176.

https://doi.org/10.1182/blood-2022-171117

Published: 2022

Journal Articles

Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience

Blood (2022) 140 (Supplement 1): 1856–1858.

https://doi.org/10.1182/blood-2022-164884

Published: 2022

NARROW

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Paired Analysis from Patients with Myeloma Elucidates Favorable CAR-T Manufacture and Phenotype, Starting from Mobilized Pre-Transplant Apheresis Vs. Non-Mobilized Apheresis after Four Prior Lines

Teclistamab Induces Favorable Responses in Patients with Relapsed and Refractory Multiple Myeloma after Prior BCMA-Directed Therapy

Selinexor Disrupts Epigenetic Programing and Modulates Immunogenicity in Multiple Myeloma

A Novel Composite Endpoint of Toxicity- and Progression-Free Survival after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma

Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium

Unveiling the Digital Landscape of CAR-T Therapies in Multiple Myeloma Using Social Media Insights

Clinician and Administrator Perspectives on Chimeric Antigen Receptor (CAR) T-Cell Therapy Outpatient Administration in Relapsed or Refractory Multiple Myeloma (RRMM) in the United States (US): A Qualitative Study

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

Single Cell RNA Sequencing of Sequential Samples before and after BCMA-Directed CAR-T Reveal Features Associated with Non-Durable Response, Exhausted T-Cells and Decreased Expression of Genes Encoding Key Surface Targets in Particular in Patients with Extramedullary Disease

Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma

Expression of Cell Surface Immunotherapy Targets across the Multiple Myeloma Disease Spectrum: Implications for Sequencing and Multi-Target Strategies

A Novel Composite Endpoint of Toxicity-Free, Progression-Free Survival (TPFS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Cost per Responder Analysis of Patients with Lenalidomide-Refractory Multiple Myeloma Who Received Cilta-Cel from the Cartitude-4 Trial

Facility-Related Healthcare Resource Utilization (HCRU) for Patients Treated with Idecabtagene Vicleucel (Ide-Cel, bb2121) in a Real-World (RW) Setting: A Single-Center Experience

Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only